Study Group: Physicians who Treat Acne Vulgaris (US)
Council Members in this Study Group: 54
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Sunil DhawanClinical Assistant Professor of Dermatology
STANFORD UNIVERSITY
Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed...
- Brian Lester
Dermatologist
Brian W Lester, MDBrian Lester, MD, is a Dermatologist in private practice in Massachusetts. His interests include clinical dermatology, cosmetic dermatology, dermatopathology, and dermatologic pharmaceuticals. He has experience with clinical trials involving a variety...
- Michael Bain
Plastic and Reconstructive Physician
Michael A Bain, MDMichael Bain, MD, MS, is a Plastic and Reconstructive Physician in private practice based in Southern California. He has experience in all areas of plastic and reconstructive surgery including bariatric, breast, cosmetic, and reconstructive surgery. Dr....
- Alan Fleischer
Professor and Chair of Dermatology
Wake Forest University School of Medicine - CCAlan Fleischer, MD, is a Professor and Chair of Dermatology at the Wake Forest University School of Medicine. In addition to his general and surgical dermatology practice, he has been the primary investigator on dozens of Phase II through Phase IV clinical...
- Kenneth Edelson
Clinical Instructor
MOUNT SINAI SCHOOL OF MEDICINE OFKenneth Edelson, MD, FAACS, is a Clinical Instructor at Mount Sinai School of Medicine and attending at The Mount Sinai Hospital. He is an NYC Dermatologist in practice for over 25 years and specializes in cosmetic dermatologic surgery and skin cancer....
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 19, 2009
Leo Pharma completes merger pact with Peplin | www.pharmabiz.com
The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.
-
Presta Trial shows good results for Enbrel
October 14, 2009
New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com
This trial showed predicatably good results for Enbrel in patients with psoriasis and psoriatic arthritis. This included improvement in signs and symptoms and quality of life. This will increase sales of Enbrel in the short term. However the two newer agents, Humira and Stelara have better efficacy, and more convenient dosing regimens. Both will be doing similar studies.
-
Probiotics and Atopic Dermatitis
April 27, 2009
Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. | www.ncbi.nlm.nih.gov
Large, well-conducted meta-analysis shows as a preventative strategy, probiotics may have a modest effect on decreasing the incidence of atopic eczema. However, in terms of treating active disease or preventing recurrence of disease, no convincing evidence supports the use of the probiotics examined thus far.
-
Will the withdrawl of Efalizumab effect the biologic market?
April 15, 2009
Efalizumab withdrawn from US Market | www.medscape.com
This article is important in that the withdrawal of efalizumab by Genentech was appropriate in view of its serious side effect of progressive multifocal leukoencephalopathy (PML). This biologic agent was already declining in usage because of its other side effects, and the presence of other strong competitors with equal or higher efficacy and less side effects. This was to be compounded by the impending release of ustekinumab
-
Aurobindo terbinafine approval- what effect will this have?
January 21, 2009
Aurobindo Pharma gets approval for Terbinafine Tablets | myiris.com
This article is important in that it confirms another terbinafine competitor to the Novartis Lamisil brand is being released. The majority of terbinafine prescriptions in North America are generic. The market for this product will be good at least until more effective oral or topical agents are released. The majority of the prescriptions are for onychomycosis (toenail fungus). The newer products will be released in 3-4 years, at which time the market for terbinafine will shrink significantly.
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Other Freestanding Healthcare Facility
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Physician - Director
- Physician - Department Chair
- Physician - Division Head
- President
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Dermatologists (US) | 616 |
| Physicians who Treat Rosacea (US) | 134 |
| Physicians who Treat Acne (US) | 302 |
| Hair Restoration Dermatologists (US) | 285 |
| Cosmetic Dermatologists (US) | 280 |
| Cosmetic Dermatologists | 349 |
| Dermatologists who Treat Psoriasis (US) | 106 |
| Users of Dermal Fillers (US) | 138 |